Page last updated: 2024-11-06

thymidine and Hepatitis B

thymidine has been researched along with Hepatitis B in 69 studies

Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

Research Excerpts

ExcerptRelevanceReference
"We performed a prospective study of 450 hepatitis B e antigen-positive pregnant women with HBV DNA levels greater than 10(6) IU/mL; 279 women received telbivudine (600 mg/d) during weeks 24 to 32 of gestation, and 171 women who were unwilling to take antiviral drugs participated as controls."9.20Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. ( Deng, G; He, D; He, Y; Huang, H; Li, J; Li, L; Pan, M; Sun, X; Tan, S; Wang, Y; Wu, Q; Yan, Z; Zeng, Y, 2015)
"There is limited data on the efficacy and outcome of telbivudine (LdT) therapy in patients with chronic hepatitis B and compensated cirrhosis."9.19Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014)
"To evaluate the efficacy and safety of telbivudine use during the second and third trimester of pregnancy for reducing hepatitis B virus (HBV) transmission from highly viremic hepatitis B e antigen-positive (HBeAg+) mothers to their fetuses."9.16[Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus]. ( Han, GR; Jiang, HX; Kan, NY; Wang, CM; Wang, GJ; Wu, MM; Yue, X, 2012)
"The aim of this work was to compare the early antiviral effectiveness of telbivudine and entecavir in the treatment of patients with hepatitis B e antigen (HBeAg)-positive HBV."9.14A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. ( Chen, YP; Dai, ZJ; Shi, KQ; Ye, C; Zheng, MH, 2010)
"BECKGROUND: Evaluate the efficacy and safety of telbivudine during the 2nd and 3rd trimester of pregnancy in intrauterine transmission of hepatitis B virus (HBV)."8.90Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. ( Chen, YP; Hocher, B; Huang, SM; Li, J; Liang, XJ; Liu, ZW; Lu, YP; Xiao, XM, 2014)
"To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus."8.02Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. ( Chen, X; Hu, Z; Lu, J; Ma, L; Wang, X; Zheng, S; Zhu, Y, 2021)
" This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA."7.85Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. ( Han, Z; Huang, M; Liu, J; Shi, H; Xia, J; Xue, J; Zhang, S; Zhu, Z, 2017)
"In our study, long-term telbivudine therapy is associated with a sustained improvement of renal function in patients with hepatitis B virus infection after living donor liver transplant."7.85A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant. ( Chen, YL; Hsieh, CE; Ko, CJ; Lin, CC; Lin, KH; Lin, PY; Ming, YZ, 2017)
"To observe the success rate of telbivudine (LdT) for the prevention of perinatal transmission of hepatitis B virus (HBV) and the incidence of alanine aminotransferase (ALT) elevation during LdT treatment and after LdT withdrawal in HBV-infected pregnant woman with high viremia in immune-tolerant phase and receiving LdT treatment at the end of pregnancy, and to evaluate the efficacy of LdT in the prevention of perinatal transmission and the safety for pregnant women."7.83[Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal]. ( Bai, H; Ding, Y; Dou, XG; Fan, YX; Han, C; Li, BJ; Li, YW; Sheng, QJ; Zhang, C, 2016)
"Data are limited for comparison of the long-term efficacy of telbivudine (LdT) between hepatitis B virus (HBV)-related compensated and decompensated cirrhosis."7.80Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. ( Li, J; Liu, J; Lu, W; Wang, J; Yang, X; Zhou, L, 2014)
"The aim of this study was to evaluate the efficacy and safety of telbivudine 600 mg/day compared with lamivudine 100 mg/day for 48 weeks of treatment in patients with hepatitis B-related cirrhosis."7.79Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. ( Chen, Y; Gao, Z; Han, Y; Han, Z; Jia, G; Li, C; Liu, J; Luo, G; Shi, Y; Xia, L; Yin, F; Zhou, X; Zhu, J, 2013)
"Tenofovir is a new effective treatment option for patients with chronic hepatitis B, but could be potentially hampered by mutations in the hepatitis B virus (HBV) polymerase conferring drug resistance."7.75The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. ( Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Sheldon, J; Tacke, F; Trautwein, C, 2009)
"beta-L-Thymidine (L-dT) and beta-L-2'-deoxycytidine (L-dC) are potent and highly specific inhibitors of hepatitis B virus (HBV) replication both in vivo and in vitro (50% effective concentrations, 0."7.71Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. ( Bridges, EG; Bryant, ML; Cretton-Scott, E; Dukhan, D; Faraj, A; Gosselin, G; Hernandez-Santiago, B; Imbach, JL; Pierra, C; Placidi, L; Rodriguez-Orengo, J; Sommadossi, JP, 2002)
"An inhibitory effect of 3'-azido-3'-deoxythymidine triphosphate on hepatitis B virus DNA polymerase was found."7.67Inhibition of hepatitis B virus DNA polymerase by 3'-azido-3'-deoxythymidine triphosphate but not by its threo analog. ( Chattopadhyaya, J; Löfgren, B; Nordenfelt, E; Oberg, B, 1987)
" LdT treatment was safe for mothers and infants, and no congenital deformities were reported."5.42Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. ( Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yang, YF; Yue, X, 2015)
"We performed a prospective study of 450 hepatitis B e antigen-positive pregnant women with HBV DNA levels greater than 10(6) IU/mL; 279 women received telbivudine (600 mg/d) during weeks 24 to 32 of gestation, and 171 women who were unwilling to take antiviral drugs participated as controls."5.20Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. ( Deng, G; He, D; He, Y; Huang, H; Li, J; Li, L; Pan, M; Sun, X; Tan, S; Wang, Y; Wu, Q; Yan, Z; Zeng, Y, 2015)
"There is limited data on the efficacy and outcome of telbivudine (LdT) therapy in patients with chronic hepatitis B and compensated cirrhosis."5.19Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014)
"To evaluate the efficacy and safety of telbivudine use during the second and third trimester of pregnancy for reducing hepatitis B virus (HBV) transmission from highly viremic hepatitis B e antigen-positive (HBeAg+) mothers to their fetuses."5.16[Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus]. ( Han, GR; Jiang, HX; Kan, NY; Wang, CM; Wang, GJ; Wu, MM; Yue, X, 2012)
"The aim of this work was to compare the early antiviral effectiveness of telbivudine and entecavir in the treatment of patients with hepatitis B e antigen (HBeAg)-positive HBV."5.14A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. ( Chen, YP; Dai, ZJ; Shi, KQ; Ye, C; Zheng, MH, 2010)
"The aim of this prospective study was to investigate the diagnostic value of ultrasound elastography for evaluating liver stiffness measurement (LSM) in 74 patients with hepatitis B virus (HBV) infection, treated with telbivudine (22 with chronic HBV infection, 32 with compensated cirrhosis and 20 with decompensated cirrhosis)."5.14The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection: a prospective study. ( Bai, XF; Gou, YZ; Jiang, W; Liu, B; Yu, HT, 2010)
"BECKGROUND: Evaluate the efficacy and safety of telbivudine during the 2nd and 3rd trimester of pregnancy in intrauterine transmission of hepatitis B virus (HBV)."4.90Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. ( Chen, YP; Hocher, B; Huang, SM; Li, J; Liang, XJ; Liu, ZW; Lu, YP; Xiao, XM, 2014)
" In the last few years the therapeutic options in chronic hepatitis B have increased and currently six treatments are authorized: standard interferon (IFN)-alpha, pegylated interferon-alpha (PEG-IFNalpha), lamivudine, adefovir, entecavir, and telbivudine."4.84[Interferon in hepatitis B]. ( García Buey, L; González Mateos, F; Moreno Otero, R, 2008)
"Idenix (formerly Novirio) and Novartis are developing two beta-L-deoxynucleosides, telbivudine and torcitabine, for the potential treatment of hepatitis B virus infection."4.82Telbivudine/Torcitabine Idenix/Novartis. ( Hodge, RA, 2004)
"To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus."4.02Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. ( Chen, X; Hu, Z; Lu, J; Ma, L; Wang, X; Zheng, S; Zhu, Y, 2021)
" This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA."3.85Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. ( Han, Z; Huang, M; Liu, J; Shi, H; Xia, J; Xue, J; Zhang, S; Zhu, Z, 2017)
"In our study, long-term telbivudine therapy is associated with a sustained improvement of renal function in patients with hepatitis B virus infection after living donor liver transplant."3.85A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant. ( Chen, YL; Hsieh, CE; Ko, CJ; Lin, CC; Lin, KH; Lin, PY; Ming, YZ, 2017)
"To observe the success rate of telbivudine (LdT) for the prevention of perinatal transmission of hepatitis B virus (HBV) and the incidence of alanine aminotransferase (ALT) elevation during LdT treatment and after LdT withdrawal in HBV-infected pregnant woman with high viremia in immune-tolerant phase and receiving LdT treatment at the end of pregnancy, and to evaluate the efficacy of LdT in the prevention of perinatal transmission and the safety for pregnant women."3.83[Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal]. ( Bai, H; Ding, Y; Dou, XG; Fan, YX; Han, C; Li, BJ; Li, YW; Sheng, QJ; Zhang, C, 2016)
"Data are limited for comparison of the long-term efficacy of telbivudine (LdT) between hepatitis B virus (HBV)-related compensated and decompensated cirrhosis."3.80Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. ( Li, J; Liu, J; Lu, W; Wang, J; Yang, X; Zhou, L, 2014)
"Myopathy or neuropathy has been associated with lamivudine/telbivudine therapy in hepatitis B patients."3.80Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion. ( Jin, S; Lv, H; Wang, Z; Xu, H; Yuan, Y; Zhang, W; Zheng, L, 2014)
"The aim of this study was to evaluate the efficacy and safety of telbivudine 600 mg/day compared with lamivudine 100 mg/day for 48 weeks of treatment in patients with hepatitis B-related cirrhosis."3.79Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. ( Chen, Y; Gao, Z; Han, Y; Han, Z; Jia, G; Li, C; Liu, J; Luo, G; Shi, Y; Xia, L; Yin, F; Zhou, X; Zhu, J, 2013)
"Telbivudine (beta-l-2'-deoxythymidine) is an orally administered nucleoside analog drug approved for the treatment of patients with chronic hepatitis B since 2006."3.77Rhabdomyolysis in a 48-year-old man with hepatitis B-induced cirrhosis. ( Dang, S; Gao, N; Jia, X; Zhang, X, 2011)
"A 27 yo male of African origin received telbivudine for hepatitis B during 3 months."3.76Myotoxicity of telbivudine in pre-existing muscle damage. ( Ay, L; Finsterer, J, 2010)
"Tenofovir is a new effective treatment option for patients with chronic hepatitis B, but could be potentially hampered by mutations in the hepatitis B virus (HBV) polymerase conferring drug resistance."3.75The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. ( Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Sheldon, J; Tacke, F; Trautwein, C, 2009)
"beta-L-Thymidine (L-dT) and beta-L-2'-deoxycytidine (L-dC) are potent and highly specific inhibitors of hepatitis B virus (HBV) replication both in vivo and in vitro (50% effective concentrations, 0."3.71Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. ( Bridges, EG; Bryant, ML; Cretton-Scott, E; Dukhan, D; Faraj, A; Gosselin, G; Hernandez-Santiago, B; Imbach, JL; Pierra, C; Placidi, L; Rodriguez-Orengo, J; Sommadossi, JP, 2002)
"An inhibitory effect of 3'-azido-3'-deoxythymidine triphosphate on hepatitis B virus DNA polymerase was found."3.67Inhibition of hepatitis B virus DNA polymerase by 3'-azido-3'-deoxythymidine triphosphate but not by its threo analog. ( Chattopadhyaya, J; Löfgren, B; Nordenfelt, E; Oberg, B, 1987)
"The incorporation of 14C-thymidine by peripheral blood lymphocytes stimulated by phytohemagglutinin (PHA) and the proportion and absolute number of E-rosettes were determined in 28 prostitutes and the results were correlated with hepatitis B virus (HBV) serology."3.66T-lymphocytes and hepatitis B serology. ( Drouga, M; Kaklamani, E; Karalis, D; Papaevangelou, G; Papoutsakis, G; Trichopoulos, D, 1978)
"In patients not requiring HAART, treatment of hepatitis B should preferably consist of drugs without activity against HIV, such as pegylated interferon or adefovir."2.44[Hepatitis B in patients with HIV infection]. ( Barreiro, P; García-Samaniego, J; Martín-Carbonero, L, 2008)
"Lamivudine was switched to telbivudine."1.42Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy. ( Akarca, US; Bademkiran, F; Duman, S; Ersoz, G; Gunsar, F; Karasu, Z; Kose, T; Ozutemiz, O; Sozbilen, M; Turan, I; Yapali, S, 2015)
" LdT treatment was safe for mothers and infants, and no congenital deformities were reported."1.42Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. ( Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yang, YF; Yue, X, 2015)
"This retrospective investigation carried out in Guangdong Province indicated that not only are anti-HBV drugs efficacious for blocking vertical transmission of HBV but also are safe for both mothers and infants when taken by fathers or mothers during the reproduction phases of insemination and pregnancy."1.40[Retrospective analysis of the efficacy and safety of anti-hepatitis B virus drugs taken during pregnancy in women from the Guangdong Province]. ( Chen, X; Gao, W; Li, D; Peng, J; Wen, F; Xia, J; Xu, C; Xu, M; Yao, Z, 2014)
"Telbivudine seemed to be a candidate for exclusive anti-HBV therapy because it exerts no significant in vitro activity against HIV."1.39In vivo antiviral activity of telbivudine against HIV-1: a case report. ( Bonadies, G; Borgia, G; Borrelli, F; Buonomo, AR; Carleo, MA; Gentile, I; Portella, G, 2013)
"Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) represents a severe condition that requires prophylaxis with specific immunoglobulin and lamivudine."1.38Telbivudin as prophylaxis for hepatitis B virus recurrence after liver transplantation: a case series in single-center experience. ( Amato, G; Calise, F; Cuomo, O; Dicostanzo, G; Lanza, AG; Marcos, A; Perrella, A; Pisaniello, D; Santaniello, W, 2012)
"Hepatitis B is a DNA virus affecting hundreds of millions of individuals worldwide."1.36Viral resistance in hepatitis B: prevalence and management. ( Chee, GM; Poordad, F, 2010)

Research

Studies (69)

TimeframeStudies, this research(%)All Research%
pre-199015 (21.74)18.7374
1990's1 (1.45)18.2507
2000's11 (15.94)29.6817
2010's41 (59.42)24.3611
2020's1 (1.45)2.80

Authors

AuthorsStudies
Li, D2
Huang, ZM1
Lu, J1
Wang, X1
Zhu, Y1
Ma, L1
Zheng, S1
Hu, Z1
Chen, X2
Shi, H1
Han, Z2
Liu, J3
Xue, J1
Zhang, S1
Zhu, Z1
Xia, J2
Huang, M2
Lin, CL1
Kao, JH1
Shi, Y1
Zhu, J1
Chen, Y1
Yin, F1
Xia, L1
Luo, G1
Gao, Z2
Jia, G1
Li, C1
Zhou, X1
Han, Y1
Lisotti, A1
Eusebi, LH1
Festi, D1
Bazzoli, F1
Mazzella, G1
Gentile, I1
Bonadies, G1
Carleo, MA1
Buonomo, AR1
Borrelli, F1
Portella, G1
Borgia, G1
Calvaruso, V1
Craxì, A1
Yang, X1
Li, J4
Zhou, L1
Wang, J1
Lu, W1
Tsai, MC1
Yu, HC1
Hung, CH1
Lee, CM1
Chiu, KW1
Lin, MT1
Tseng, PL1
Chang, KC1
Yen, YH1
Chen, CH1
Hu, TH1
Lu, YP1
Liang, XJ1
Xiao, XM1
Huang, SM1
Liu, ZW1
Hocher, B1
Chen, YP2
Tillmann, HL1
Patel, K1
Xu, H1
Wang, Z1
Zheng, L1
Zhang, W1
Lv, H1
Jin, S1
Yuan, Y1
Peng, J1
Xu, M1
Yao, Z1
Xu, C1
Wen, F1
Gao, W1
Wu, Q1
Huang, H1
Sun, X1
Pan, M1
He, Y1
Tan, S1
Zeng, Y1
Li, L1
Deng, G1
Yan, Z1
He, D1
Wang, Y1
Han, GR2
Jiang, HX2
Yue, X2
Ding, Y2
Wang, CM2
Wang, GJ2
Yang, YF1
Hollinger, FB1
Turan, I1
Yapali, S1
Bademkiran, F1
Kose, T1
Duman, S1
Sozbilen, M1
Gunsar, F1
Ersoz, G1
Akarca, US1
Ozutemiz, O1
Karasu, Z1
Su, F1
Dai, J2
Yang, S1
Jiang, X1
Cui, X1
Ning, H1
Zhang, Y1
Hu, P1
Qi, X1
Ren, H1
Mao, RC1
Zhang, JM1
Zhang, MY1
Zhu, GQ1
Shi, KQ2
Zheng, JN1
Cheng, Z1
Zou, ZL1
Huang, HH1
Chen, FY1
Zheng, MH2
Sheng, QJ1
Li, BJ1
Bai, H1
Zhang, C1
Han, C1
Fan, YX1
Li, YW1
Dou, XG1
Lin, KH1
Chen, YL1
Lin, PY1
Hsieh, CE1
Ko, CJ1
Lin, CC1
Ming, YZ1
Chawla, PS1
Kochar, MS1
Beckebaum, S1
Sotiropoulos, GC1
Gerken, G1
Cicinnati, VR1
García Buey, L1
González Mateos, F1
Moreno Otero, R1
Barreiro, P1
Martín-Carbonero, L1
García-Samaniego, J1
Fontana, RJ2
Amini-Bavil-Olyaee, S1
Herbers, U1
Sheldon, J1
Luedde, T1
Trautwein, C1
Tacke, F1
Montineri, A1
Nigro, L1
Chiarenza, A1
Larocca, L1
La Rosa, R1
Iacobello, C1
Di Raimondo, F1
Fatuzzo, F1
Liu, FJ1
Liu, L1
Zhou, TY1
Lei, J1
Xu, L1
Liu, C1
Chen, EQ1
Tang, H1
Poordad, F1
Chee, GM1
Dai, ZJ1
Ye, C1
Zhang, HY1
Liu, ZG1
Zhang, Z1
Gong, HY1
Finsterer, J1
Ay, L1
Mallet, V1
Vallet-Pichard, A1
Pol, S1
Gou, YZ1
Liu, B1
Jiang, W1
Yu, HT1
Bai, XF1
Dang, S1
Gao, N1
Zhang, X1
Jia, X1
Gaynor, JW1
Cosstick, R1
Giles, M1
Visvanathan, K1
Sasadeusz, J1
García-Alonso, FJ1
Martín-Mateos, RM1
Moreira Vicente, V1
Singal, AK1
Kan, NY1
Wu, MM1
Dusheiko, G1
Perrella, A1
Lanza, AG1
Santaniello, W1
Pisaniello, D1
Dicostanzo, G1
Calise, F1
Amato, G1
Marcos, A1
Cuomo, O1
Huang, Y1
Wu, H1
Wu, S1
Fu, D1
Ma, Y1
Shen, X1
Morando, F1
Rosi, S1
Fasolato, S1
Cavallin, M1
Gola, E1
Gatta, A1
Angeli, P1
Chen, R1
Liu, SR1
Zhang, SY1
Tao, CJ1
Hodge, RA1
Niederau, C1
Hou, JL1
Sun, J1
Wang, C1
Warnatz, H1
Scheiffarth, F1
Wolf, F1
Schmidt, HJ1
Cote, PJ1
Gerin, JL1
Bryant, ML2
Bridges, EG2
Placidi, L2
Faraj, A2
Loi, AG1
Pierra, C2
Dukhan, D2
Gosselin, G2
Imbach, JL2
Hernandez, B1
Juodawlkis, A1
Tennant, B1
Korba, B1
Cote, P1
Marion, P1
Cretton-Scott, E2
Schinazi, RF1
Sommadossi, JP2
Hernandez-Santiago, B1
Rodriguez-Orengo, J1
Kaklamanis, E1
Trichopoulos, D2
Papaevangelou, G2
Drouga, M2
Karalis, D2
Moritsugu, Y1
Gold, JW1
Wagner, J1
Dodd, RY1
Purcell, RH1
Kaklamani, E1
Papoutsakis, G1
Masi, M1
Paolucci, P1
Timoncini, G1
Fantini, MP1
Chiodo, F1
Franceschi, C1
Wicks, RC1
Kohler, PF1
Singleton, JW1
Cappel, R1
Clinet, G1
Thiry, L1
Greeman, RL1
Robinson, WS1
Vyas, GN1
Fiume, L1
Bassi, B1
Busi, C1
Mattioli, A1
Spinosa, G1
Degrassi, A1
Mariani, E1
Roda, P1
Miniero, R1
Capelli, M1
Honorati, MC1
Astaldi, A1
Facchini, A1
Nordenfelt, E1
Löfgren, B1
Chattopadhyaya, J1
Oberg, B1
Laiwah, AA1
Kissling, M1
Speck, B1
Doshi, J1
Luisada-Opper, A1
Leevy, CM1
Millman, I1
Agarwal, SS1
Bugbee, SJ1
Blumberg, BS1
Loeb, LA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy[NCT02995005]Phase 1/Phase 298 participants (Actual)Interventional2018-05-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

13 reviews available for thymidine and Hepatitis B

ArticleYear
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepat

2014
Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis.
    Clinical laboratory, 2014, Volume: 60, Issue:4

    Topics: Antiviral Agents; Female; Hepatitis B; Humans; Infant, Newborn; Infectious Disease Transmission, Ver

2014
Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Oncotarget, 2016, May-24, Volume: 7, Issue:21

    Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hepa

2016
What's new in clinical pharmacology and therapeutics.
    WMJ : official publication of the State Medical Society of Wisconsin, 2008, Volume: 107, Issue:2

    Topics: Abatacept; Acetanilides; Amides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antipark

2008
Hepatitis B and liver transplantation: 2008 update.
    Reviews in medical virology, 2009, Volume: 19, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B Vaccines; Hu

2009
[Interferon in hepatitis B].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Guanine; H

2008
[Hepatitis B in patients with HIV infection].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deox

2008
The impact of human immunodeficiency virus on viral hepatitis.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitab

2011
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
    Antiviral therapy, 2011, Volume: 16, Issue:5

    Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatiti

2011
[Pharmacological treatment of acute hepatitis B].
    Medicina clinica, 2012, May-19, Volume: 138, Issue:14

    Topics: Acute Disease; Adenine; Antiviral Agents; Guanine; Hepatitis B; Humans; Lamivudine; Nucleosides; Org

2012
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combin

2012
A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:3

    Topics: Antiviral Agents; Hepatitis B; Humans; Lamivudine; Liver Cirrhosis; Nucleosides; Nucleotides; Revers

2013
Telbivudine/Torcitabine Idenix/Novartis.
    Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:2

    Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drugs, Investigational; Hepatitis B; Hepatitis

2004

Trials

7 trials available for thymidine and Hepatitis B

ArticleYear
Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Disease Progression; DNA, Viral; Female; Guanin

2014
Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Female; Hepatitis B; Hepatitis B Surface Ant

2015
A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Clinical therapeutics, 2010, Volume: 32, Issue:4

    Topics: Adult; Antiviral Agents; China; DNA, Viral; Female; Guanine; Hepatitis B; Hepatitis B e Antigens; He

2010
[Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:6

    Topics: Adult; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; Female; Follow-Up Studies; Guanine

2010
The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection: a prospective study.
    The Journal of international medical research, 2010, Volume: 38, Issue:6

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Asian People; China; Demography; El

2010
[Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:3

    Topics: Adult; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Humans; Infectious Disease Transmission,

2012
[Efficacy of telbivudine in blocking the vertical transmission and the safety observation of discontinuing treatment time after delivery on mother infected with HBV].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:9

    Topics: Adult; Antiviral Agents; Female; Hepatitis B; Humans; Infectious Disease Transmission, Vertical; Mot

2012

Other Studies

49 other studies available for thymidine and Hepatitis B

ArticleYear
[A case report of severe edema in both lower limbs of hepatitis B patients with normal renal function induced by telbivudine].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019, 11-20, Volume: 27, Issue:11

    Topics: Antiviral Agents; DNA, Viral; Edema; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans;

2019
Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine.
    Gut and liver, 2021, 11-15, Volume: 15, Issue:6

    Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hep

2021
Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Nov-02, Volume: 23

    Topics: Adenine; Adult; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B; H

2017
Prevention of mother-to-child transmission: the key of hepatitis B virus elimination.
    Hepatology international, 2018, Volume: 12, Issue:2

    Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Humans; Immunization Programs; Infant, New

2018
Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
    Journal of viral hepatitis, 2013, Volume: 20 Suppl 1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens;

2013
Treatment with telbivudine for fulminant hepatitis B.
    Journal of digestive diseases, 2013, Volume: 14, Issue:11

    Topics: Acute Disease; Adult; Antiviral Agents; Female; Hepatitis B; Humans; Liver Failure, Acute; Telbivudi

2013
In vivo antiviral activity of telbivudine against HIV-1: a case report.
    Le infezioni in medicina, 2013, Volume: 21, Issue:3

    Topics: Acute Disease; Adenine; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B

2013
Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cholinesterases; Drug Resistance, Viral;

2014
Therapy of acute and fulminant hepatitis B.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Antiviral Agents; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatiti

2014
Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion.
    Journal of clinical pathology, 2014, Volume: 67, Issue:11

    Topics: Adult; Aged, 80 and over; Antiviral Agents; Biopsy; DNA, Mitochondrial; Female; Hepatitis B; Humans;

2014
[Retrospective analysis of the efficacy and safety of anti-hepatitis B virus drugs taken during pregnancy in women from the Guangdong Province].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:7

    Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B; Hepatitis B virus; Humans; Infant; Infant,

2014
Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:9

    Topics: Adult; Antiviral Agents; Case-Control Studies; China; DNA, Viral; Female; Hepatitis B; Hepatitis B S

2015
Should Evidence-based Medicine Be Used to Design Clinical Practice Guidelines for the Prevention of Perinatal Transmission of Hepatitis B Virus From Hepatitis B e Antigen-Positive Mothers?
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:6

    Topics: Antiviral Agents; Female; Hepatitis B; Humans; Infectious Disease Transmission, Vertical; Male; Preg

2015
Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015, Volume: 21, Issue:8

    Topics: Aged; Antiviral Agents; Diabetes Mellitus; Drug Substitution; End Stage Liver Disease; Female; Glome

2015
Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
    Journal of medical virology, 2015, Volume: 87, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Genetic Variati

2015
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2016, Volume: 22, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; China; Female; Follow-Up Studies; Guanine; Hepatitis B; H

2016
[Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016, Volume: 24, Issue:4

    Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Infant; In

2016
A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2017, Volume: 15, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Cross-Sectional Studies; End Stage Liver Dise

2017
Hepatitis B: a "GLOBAL" health challenge.
    Gastroenterology, 2009, Volume: 136, Issue:2

    Topics: Antiviral Agents; DNA, Viral; Global Health; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Nuc

2009
The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:4

    Topics: Adenine; Anti-HIV Agents; Cell Line, Tumor; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Gua

2009
Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy

2010
Application of hepatitis B virus replication mouse model.
    World journal of gastroenterology, 2010, Apr-28, Volume: 16, Issue:16

    Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Enzyme-Linked Immunosorbe

2010
Viral resistance in hepatitis B: prevalence and management.
    Current gastroenterology reports, 2010, Volume: 12, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genetic Testing; Genotype; Guanine; Hepatitis B;

2010
Myotoxicity of telbivudine in pre-existing muscle damage.
    Virology journal, 2010, Nov-17, Volume: 7

    Topics: Adult; Antiviral Agents; Creatine Kinase; Hepatitis B; Humans; Male; Muscle, Skeletal; Muscular Dise

2010
Rhabdomyolysis in a 48-year-old man with hepatitis B-induced cirrhosis.
    The American journal of the medical sciences, 2011, Volume: 342, Issue:1

    Topics: Acute Kidney Injury; Antiviral Agents; Fatal Outcome; Fibrosis; Hepatitis B; Humans; Male; Middle Ag

2011
Dinucleotides containing 3'-S-phosphorothiolate linkages.
    Methods in molecular biology (Clifton, N.J.), 2011, Volume: 764

    Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dinucleoside Phosphates; Endonucleases; Hepatitis B; He

2011
Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis?
    Lancet (London, England), 2012, May-26, Volume: 379, Issue:9830

    Topics: Antiviral Agents; Developing Countries; Female; Hepatitis B; Humans; Infant; Infant, Newborn; Infect

2012
Telbivudin as prophylaxis for hepatitis B virus recurrence after liver transplantation: a case series in single-center experience.
    Transplantation proceedings, 2012, Volume: 44, Issue:7

    Topics: Adult; Case-Control Studies; Female; Hepatitis B; Humans; Liver Transplantation; Male; Middle Aged;

2012
Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene.
    Journal of medical virology, 2013, Volume: 85, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B; Hepatitis B An

2013
[New German and American guidelines for therapy of hepatitis B. Discrepancies and similarities].
    Medizinische Klinik (Munich, Germany : 1983), 2007, Sep-15, Volume: 102, Issue:9

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Drug Th

2007
[Several important issues on drug resistance of hepatitis B virus].
    Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:9

    Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; Humans; Nucleosides; Pyrim

2007
Autoradiographic experiments concerning the importance of mononuclear cells in experimental hepatitis.
    Journal of immunology (Baltimore, Md. : 1950), 1967, Volume: 98, Issue:2

    Topics: Animals; Autoradiography; Carbon Tetrachloride Poisoning; Hepatitis B; Liver; Lymphocytes; Mice; Thy

1967
In vitro activation of woodchuck lymphocytes measured by radiopurine incorporation and interleukin-2 production: implications for modeling immunity and therapy in hepatitis B virus infection.
    Hepatology (Baltimore, Md.), 1995, Volume: 22, Issue:3

    Topics: Animals; Antigens, Viral; Cells, Cultured; Culture Media; Disease Models, Animal; Epitopes; Hepatiti

1995
Antiviral L-nucleosides specific for hepatitis B virus infection.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:1

    Topics: Animals; Anti-HIV Agents; Antiviral Agents; Bone Marrow Cells; Cell Line; Deoxyadenosines; Deoxycyti

2001
Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:6

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Deoxycytidine; Ha

2002
Letter: T lymphocytes in HBAg carriers and responders.
    Lancet (London, England), 1975, Mar-22, Volume: 1, Issue:7908

    Topics: Antibodies, Viral; Carrier State; Female; Hepatitis B; Hepatitis B Antigens; Humans; Immune Adherenc

1975
Hepatitis B core antigen. Detection of antibody by radioimmunoprecipitation.
    Journal of immunology (Baltimore, Md. : 1950), 1975, Volume: 114, Issue:6

    Topics: Animals; Antibodies; Antibodies, Viral; Carrier State; Centrifugation, Density Gradient; Complement

1975
T-lymphocytes and hepatitis B serology.
    Infection, 1978, Volume: 6, Issue:6

    Topics: Carbon Radioisotopes; Female; Hepatitis B; Hepatitis B Surface Antigens; Humans; Lectins; Rosette Fo

1978
[Chronic persistent HBsAG positive hepatitis in children. I. Subpopulations of T and B lymphocytes].
    Bollettino dell'Istituto sieroterapico milanese, 1978, Sep-30, Volume: 57, Issue:4

    Topics: B-Lymphocytes; Child; Child, Preschool; Chronic Disease; Female; Hepatitis B; Hepatitis B Surface An

1978
Thymus-derived lymphocytes in type B acute viral hepatitis and healthy carriers of hepatitis B surface antigen (HBsAg).
    The American journal of digestive diseases, 1975, Volume: 20, Issue:6

    Topics: Carrier State; Cells, Cultured; Hepatitis B; Hepatitis B Antigens; Humans; Immune Adherence Reaction

1975
[Letter: Demonstration of anti-ADN polymerase antibodies during serum hepatitis].
    La Nouvelle presse medicale, 1975, Mar-08, Volume: 4, Issue:10

    Topics: Antibodies; DNA Nucleotidyltransferases; Hepatitis B; Humans; Immunoglobulin G; Immunoglobulin M; Th

1975
A sensitive test for antibody against the hepatitis B core antigen (anti-HB-c).
    Vox sanguinis, 1975, Volume: 29, Issue:1

    Topics: Animals; Antibodies; Carrier State; Centrifugation, Density Gradient; DNA Nucleotidyltransferases; G

1975
Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-beta-D-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells.
    Biochemical pharmacology, 1986, Mar-15, Volume: 35, Issue:6

    Topics: Animals; Arabinonucleotides; Bone Marrow; DNA; Female; Hepatitis B; Intestinal Mucosa; Liver; Mice;

1986
Specific lymphocyte proliferative response in vitro after cDNA HBsAg immunization.
    Advances in experimental medicine and biology, 1989, Volume: 257

    Topics: Adult; Concanavalin A; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; He

1989
Inhibition of hepatitis B virus DNA polymerase by 3'-azido-3'-deoxythymidine triphosphate but not by its threo analog.
    Journal of medical virology, 1987, Volume: 22, Issue:3

    Topics: Antiviral Agents; Carrier State; Dideoxynucleotides; Hepatitis B; Hepatitis B virus; Humans; Nucleic

1987
Lymphocyte transformation by Australia antigen.
    Lancet (London, England), 1971, Aug-28, Volume: 2, Issue:7722

    Topics: Antibody Formation; Antigens; Carbon Isotopes; Complement Fixation Tests; Hepatitis A; Hepatitis B;

1971
Lymphocyte transforming activity in the serum of patients with hepatic disease.
    Vox sanguinis, 1971, Volume: 21, Issue:3

    Topics: Autoradiography; Cholestasis; Culture Techniques; Cytidine; DNA Replication; Globulins; Hepatitis; H

1971
Microsomal pentobarbital hydroxylase activity in acute viral hepatitis.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1972, Volume: 140, Issue:2

    Topics: Biopsy; Carbon Isotopes; Hepatitis A; Hepatitis B; Hepatitis B Antigens; Humans; Liver Function Test

1972
Lymphocyte transformation and hepatitis. II. Lack of direct in vitro inhibition by purified Australia antigen.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1971, Volume: 138, Issue:1

    Topics: Cold Temperature; DNA Nucleotidyltransferases; DNA Replication; Hepatitis A; Hepatitis B; Hepatitis

1971